Guangwen Lu

Nov 19, 2024 | nature.com | Weiqi Hong |Aqu Alu |Zimin Chen |Hongbo Hu |Haohao Dong |Jian Lei | +8 more

AbstractThe mucosal immune response plays a crucial role in the prevention of respiratory viruses. Given the risk of recurrent SARS-CoV-2 infections in the population, the rapid development of next-generation intranasal COVID-19 vaccines with high safety and efficacy is paramount. In the current study, we developed a protein-based intranasal vaccine comprising the XBB.1.5 receptor binding domain (RBD)-derived trimeric recombinant protein (RBDXBB.1.5-HR) and an MF59-like oil-in-water adjuvant.

Mar 5, 2024 | nature.com | Dan Zhang |Lunzhi Dai |Guangwen Lu |Lu Chen

AbstractPrecise identification and quantification of amino acids is crucial for many biological applications. Here we report a copper(II)-functionalized Mycobacterium smegmatis porin A (MspA) nanopore with the N91H substitution, which enables direct identification of all 20 proteinogenic amino acids when combined with a machine-learning algorithm. The validation accuracy reaches 99.1%, with 30.9% signal recovery.

May 9, 2023 | nature.com | Weiqi Hong |Wei Qing Wang |Shuaiyao Lu |Guangwen Lu |Xiangrong Song

AbstractMucosal immunity plays a significant role in the first-line defense against viruses transmitted and infected through the respiratory system, such as SARS-CoV-2. However, the lack of effective and safe adjuvants currently limits the development of COVID-19 mucosal vaccines. In the current study, we prepare an intranasal vaccine containing cationic crosslinked carbon dots (CCD) and a SARS-CoV-2 antigen, RBD-HR with spontaneous antigen particlization.